Portage Biotech Stock Performance
| PRTG Stock | USD 3.98 0.06 1.49% |
Portage Biotech holds a performance score of 5 on a scale of zero to a hundred. The company holds a Beta of -0.18, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Portage Biotech are expected to decrease at a much lower rate. During the bear market, Portage Biotech is likely to outperform the market. Use Portage Biotech potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Portage Biotech.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Portage Biotech are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak basic indicators, Portage Biotech reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.97) | Five Day Return (5.24) | Year To Date Return (89.47) | Ten Year Return (97.88) | All Time Return (99.99) |
Last Split Factor 1:20 | Dividend Date 2020-06-04 | Last Split Date 2024-08-15 |
1 | Paessler GmbH announces the multi-platform probe for PRTG, extending monitoring capabilities to Linux-based IT environments and beyond | 11/04/2024 |
2 | Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 | 11/26/2024 |
| Begin Period Cash Flow | 10.5 M |
Portage |
Portage Biotech Relative Risk vs. Return Landscape
If you would invest 339.00 in Portage Biotech on September 5, 2024 and sell it today you would earn a total of 59.00 from holding Portage Biotech or generate 17.4% return on investment over 90 days. Portage Biotech is currently generating 1.1956% in daily expected returns and assumes 16.9668% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Portage, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Portage Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Portage Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Portage Biotech, and traders can use it to determine the average amount a Portage Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0705
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PRTG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 16.97 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.2 actual daily | 23 77% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Portage Biotech is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Portage Biotech by adding it to a well-diversified portfolio.
Portage Biotech Fundamentals Growth
Portage Stock prices reflect investors' perceptions of the future prospects and financial health of Portage Biotech, and Portage Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Portage Stock performance.
| Return On Equity | -1.91 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.79 M | ||||
| Shares Outstanding | 1.12 M | ||||
| Price To Book | 3.19 X | ||||
| EBITDA | (18.2 M) | ||||
| Net Income | (75.34 M) | ||||
| Cash And Equivalents | 21.18 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 47 K | ||||
| Current Ratio | 11.73 X | ||||
| Book Value Per Share | 4.07 X | ||||
| Cash Flow From Operations | (14.3 M) | ||||
| Earnings Per Share | (68.17) X | ||||
| Market Capitalization | 4.53 M | ||||
| Total Asset | 7.78 M | ||||
| Retained Earnings | (239.32 M) | ||||
| Working Capital | 4.82 M | ||||
About Portage Biotech Performance
By analyzing Portage Biotech's fundamental ratios, stakeholders can gain valuable insights into Portage Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Portage Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Portage Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (9.68) | (9.20) | |
| Return On Capital Employed | (3.73) | (3.91) | |
| Return On Assets | (9.68) | (9.20) | |
| Return On Equity | (18.73) | (17.80) |
Things to note about Portage Biotech performance evaluation
Checking the ongoing alerts about Portage Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Portage Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Portage Biotech is way too risky over 90 days horizon | |
| Portage Biotech appears to be risky and price may revert if volatility continues | |
| Portage Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (75.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Portage Biotech currently holds about 21.18 M in cash with (14.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25. | |
| Portage Biotech has a frail financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 |
- Analyzing Portage Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Portage Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Portage Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Portage Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Portage Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Portage Biotech's stock. These opinions can provide insight into Portage Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Portage Stock analysis
When running Portage Biotech's price analysis, check to measure Portage Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Portage Biotech is operating at the current time. Most of Portage Biotech's value examination focuses on studying past and present price action to predict the probability of Portage Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Portage Biotech's price. Additionally, you may evaluate how the addition of Portage Biotech to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |